Avapritinib Data Show Durable Benefits Including QOL in Indolent Systemic Mastocytosis: Lauren Madigan, MD

This content was developed independently and is not endorsed by the American Academy of Dermatology.

At the American Academy of Dermatology (AAD) 2026 Annual Meeting, Lauren Madigan, MD, associate professor of dermatology, University of Utah, discussed long-term data from the PIONEER (NCT03731260) study, evaluating the efficacy and safety of avapritinib (Ayvakit; Blueprint Medicines Corporation) in patients with indolent systemic mastocytosis.

The study reported sustained improvements across both patient-reported outcomes and objective skin measures. Clinically relevant end points included body surface area involvement, lesional density, and lesional color, all of which showed notable and persistent improvement over time. These gains were accompanied by a continued safe and well-tolerated profile, underscoring the potential for long-term use in a chronic disease setting.

A key feature of the trial was the systematic use of the Indolent Systemic Mastocytosis Symptom Assessment Form, which captures 11 symptom domains on a scale of 0 to 10. Skin-related symptoms—fixed skin lesions, flushing, and itching—comprise 3 of these domains, yielding a skin score range of 0 to 30 per day. Patients reported meaningful reductions in these skin symptom scores over the course of therapy.

Objective skin assessments were conducted using serial photography, evaluated in 2 complementary ways: an artificial intelligence–based algorithm quantified lesional density and skin area involvement, while a blinded committee of board-certified dermatologists with expertise in mastocytosis evaluated lesional color and quality. Both approaches confirmed reductions in lesion density and progressive lightening of lesional color in the most affected areas.

Importantly, improvements in skin outcomes correlated closely with a mastocytosis-specific quality of life (QOL) index, reinforcing the central role of skin disease burden in overall patient well-being. Madigan reported that patients often describe avapritinib as life-changing, citing not only better skin outcomes but also benefits across gastrointestinal and neurocognitive domains.

Madigan believes these findings position avapritinib as a paradigm-shifting, disease-targeted therapy that directly addresses the KIT D816V–driven clone, offering durable symptom control and QOL gains in a population previously limited to symptomatic management.